Hoth Therapeutics rises on positive mid-stage trial data for skin toxicity treatment

Rocket One

07/01/2025 14:20

** Shares of drug developer Hoth Therapeutics  HOTH.O  jump
96.4% to $1.61 premarket
    ** Co announces positive interim safety and efficacy results
from a mid-stage trial testing its experimental treatment to
treat skin toxicity caused due to side effects of cancer
treatments 
    ** Co was testing the treatment, HT-001, to address skin
toxicities linked to a type of cancer medication called EGFR
inhibitors
    ** Data from the study shows that 100% of patients enrolled
in the trial had significant skin toxicity improvement by six
weeks 
    ** 66% of patients reported reduced pain and itching scores
- HOTH 
    ** Co says no treatment-related adverse effects have been
reported
    ** Up to last close, stock had fallen ~47% in the past 12
months

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))